Apr. 1, 2013 ? Loop diuretics, more commonly known as water pills, are the most widely prescribed heart failure medications, but few studies had extensively compared their effectiveness until Yale School of Medicine researchers examined three approved loop diuretics and found that even though one of them might offer more benefit, it is rarely prescribed.
Published in the April 1 early edition of the Journal of the American College of Cardiology, the research compared the potential benefits of using one of three loop diuretics: toresemide, furosemide, and bumetanide.
"Loop diuretics are a cornerstone of heart failure treatment, so it is vital to understand the comparative effectiveness and real-world use of the drugs within this class," said lead author Dr. Behnood Bikdeli, postdoctoral associate in cardiovascular medicine at the Yale Center for Outcomes Research and Evaluation (CORE).
With over 5 million Americans suffering from heart failure, Bikdeli said that improving existing treatment options is key to providing the best care.
The team found that among 274,515 hospitalizations for heart failure during 2009 and 2010 across a large group of U.S. hospitals, 92% received loop diuretics during their hospital stay. Of those, 87% received furosemide as their only loop diuretic, 3% received bumetanide, and only 0.4% received torsemide, while 10% received a combination of these agents.
Although torsemide is slightly more expensive, the few available studies suggest that it lasts longer, is better tolerated, and might be associated with better clinical outcomes compared with the two other available water pills.
"There appears to be potential benefits from using torsemide compared with furosemide, but it is rarely used in practice," said Bikdeli. "Furosemide is the dominantly used loop diuretic in practice; however, if the potential advantages of torsemide over furosemide are proven in subsequent comparative effectiveness studies, this drug might become the preferred treatment of chronic heart failure."
Other authors on the study include Kelly Strait, Kumar Dharmarajan, Chohreh Partovian, Steven Coca, Nancy Kim, Shu-Xia Li, Jeffrey Testani, Usman Khan, and Harlan Krumholz.
Share this story on Facebook, Twitter, and Google:
Other social bookmarking and sharing tools:
Story Source:
The above story is reprinted from materials provided by Yale University. The original article was written by Karen N. Peart.
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
Journal Reference:
- Behnood Bikdeli, Kelly M. Strait, Kumar Dharmarajan, Chohreh Partovian, Steven G. Coca, Nancy Kim, Shu-Xia Li, Jeffrey M. Testani, Usman Khan, Harlan M. Krumholz. Dominance of Furosemide for Loop Diuretic Therapy in Heart Failure. Journal of the American College of Cardiology, 2013; 61 (14): 1549 DOI: 10.1016/j.jacc.2012.12.043
Note: If no author is given, the source is cited instead.
Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.
Source: http://feeds.sciencedaily.com/~r/sciencedaily/~3/XEFp3w63zFg/130401161426.htm
Olympus Has Fallen Arnold Palmer Invitational 2013 arnold palmer invitational Chinua Achebe The Croods ashley greene marquette university
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.